All.Can – changing cancer care together

All.Can is an international initiative working to improve efficiency in cancer care by focusing on what really matters to patients. For more information, visit the All.Can website.


With the growing prevalence of cancer and ongoing pressures on healthcare budgets, there is a challenge to find sustainable solutions and improve efficiency in cancer care.

Current approaches to cancer care may not be sufficient for tomorrow. We must find new ways to maximise resources, ensuring that the needs of the patient are always at the core of cancer care. This means eliminating elements that bring little or no benefit to patients while prioritising interventions that confer meaningful benefits to patients.


20% of healthcare spending is estimated to be wasted on ineffective interventions

Reducing inefficiency could lead to an average gain of 2 life years in industrialised countries

1 in 3 cancer patients don’t receive pain medication appropriate to their pain level

What we achieved

HPP acted as secretariat for All.Can from the initiative’s inception in late 2016 until its incorporation as a not-for-profit association in May 2020.

As secretariat, HPP providing operational support to All.Can’s international steering committee and members. Members come from all sectors relevant to cancer care, including patient organisations, policymakers, healthcare professionals, research and industry representatives. It also support the national All.Can initiatives across Europe, Australia, Canada and South America, which are represented on the international initiative through the National Initiatives Working Group.

HPP led the development of the inaugural All.Can policy report in January 2017, which was adapted into a peer-reviewed paper published in the Journal of Cancer Policy. There have been several further All.Can publications and events, including posters at the European Society for Medical Oncology (ESMO) Congress, sessions at the European Health Forum Gastein in 2017 and 2018, and articles in The Parliament Magazine, Open Access Government, Brain Tumour magazine and EuroHealth.

In 2018, HPP worked closely with Quality Health to conduct the All.Can patient survey across 10 countries to gain patient insights on where inefficiency occurs across the cancer care pathway. The findings were published in July 2019, with coverage in numerous news and healthcare publications including an opinion piece in BMJ.

When All.Can International was formally incorporated as a not-for-profit association in Belgium, HPP handed over the secretariat function to Interel Association Management. HPP continues to partner with All.Can International on a range of research projects. Chief among these is the All.Can efficiency hub, which brings together examples of best practice in improving efficiency in cancer care from across the world. HPP is also currently leading on the development of a new All.Can policy paper, looking at the role of data in improving efficiency in cancer care.

For more information, visit the All.Can website.

Key partners and stakeholders

  • Matti Aapro, Clinique de Genolier, Switzerland
  • Sangeeta Agarawal, Helpsy
  • Tit Albreht, Institute of Public Health, Slovenia
  • Kathy Barnard, Save Your Skin Foundation
  • Antonella Cardone, European Cancer Patient Coalition
  • Szymon Chrostowski, Polish Cancer Patient Coalition
  • David Duplay, Medtera Solutions
  • Alex Filicevas, World Bladder Cancer Patient Coalition
  • Stefan Gijssels, Digestive Cancers Europe
  • Rainer Hess, GVG-Committee on Health Goals
  • Matthew Hickey, Intacare International Ltd
  • Petra Hoogendoorn, Goings-On
  • Vivek Muthu, Marivek Healthcare Consulting, UK
  • Kathy Oliver, International Brain Tumour Alliance
  • Richard Price, European CanCer Organisation (ECCO)
  • Natalie Richardson, Save Your Skin Foundation
  • Christobel Saunders, University of Western Australia
  • Thomas Szucs, University of Basel
  • Jan van Meerbeeck, Antwerp University Hospital
  • Lieve Wierinck, Former MEP
  • Ioana Enache, Baxter
  • Caroline Falciola, Roche
  • Aleksandra Krygiel-Nael, Johnson & Johnson
  • Titta Rosvall-Puplett, Bristol-Myers Squibb
  • Stefan Weber, Amgen
  • Matthijs Van Meerveld, MSD
The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Roche (major sponsor), Amgen, MSD and Johnson & Johnson (sponsors), and Baxter (contributor), with additional non-financial (in kind) support from Helpsy, Intacare and Goings-On.